Capecitabine and Bevacizumab ± Vinorelbine in Metastatic Breast Cancer
Status:
Completed
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
The aim of the trial is to detect the superiority of the triple combination of capecitabine,
bevacizumab and vinorelbine versus the combination of capecitabine and bevacizumab in
patients with metastatic breast cancer. 600 patients, 300 in each treatment group, are
treated until progression of disease to determine PFS.
Phase:
Phase 3
Details
Lead Sponsor:
iOMEDICO AG
Collaborators:
Arbeitsgemeinschaft fur Internistische Onkologie Arbeitskreis Klinische Studien Roche Pharma AG